Newsfeeds - Spark Newswire

1 minute read

News

Bausch Health Continuing Process Toward Separating Bausch + Lomb

Today, 8:22 PM

Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb

BHC

1 minute read

Bausch Health to Appeal XIFAXAN Patent Decision to U.S. Court of Appeals for the Federal Circuit, Says Expects Decision To Issue Within 12-18 Months

By Michael Horton

Today, 8:22 PM

Bausch Health Companies Inc. (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court

BHC

1 minute read

BMO Capital Maintains Market Perform on Bausch Health Companies, Lowers Price Target to $8

By Benzinga Newsdesk

Today, 8:22 PM

BMO Capital analyst Gary Nachman maintains Bausch Health Companies (NYSE:BHC) with a Market Perform and lowers the price target from $15 to $8.

BHC

1 minute read

RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $4.5

By Benzinga Newsdesk

Today, 8:22 PM

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price target from $5 to $4.5.

BHC

1 minute read

Legal
News

Today Announced The U.S. District Court Of Delaware Issued An Oral Order In The Matter Of Salix Pharmaceuticals, Ltd. Et Al V. Norwich Pharmaceuticals

By Benzinga Newsdesk

Today, 8:22 PM

Bausch Health Companies Inc. (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix

BHC

2 minute read

Bausch + Lomb Corporation Priced 35M Share IPO @$18/Share

By Charles Gross

Today, 8:22 PM

Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), today announced the pricing of its initial public offering ("IPO") of 35,000,000 common shares at a public offering price of $18.00 per share.

BHC

3 minute read

Bausch + Lomb Presents Data From Second Pivotal Phase 3 Trial Of Investigational Treatment NOV03 At The Association For Research In Vision And Ophthalmology Annual Meeting

By Benzinga Newsdesk

Today, 8:22 PM

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular

BHC

2 minute read

IPOs
News

Bausch Health Highlights Filing Of Registration Statement, Prelim. Prospectus For Proposed IPO

By Benzinga Newsdesk

Today, 8:22 PM

Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch +

BHC

1 minute read

RBC Capital Maintains Outperform on Bausch Health Companies, Lowers Price Target to $40

By Benzinga Newsdesk

Today, 8:22 PM

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Outperform and lowers the price target from $41 to $40.

BHC

2 minute read

News

Bausch Health’s Canada Unit Reports Its Dermatology Unit Launched New Topical Prescription Treatment For Acne Vulgaris ARAZLO, Available Across Canada

By Benzinga Newsdesk

Today, 8:22 PM

Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health" or the "Company"), and its dermatology division, one of the largest prescription

BHC